Atyr stocks

**No results were found for ATYR stocks**. However, based on relevant information, aTyr Pharma (NASDAQ: ATYR) is a clinical-stage biotechnology company with a focus on developing first-in-class medicines from its proprietary tRNA synthetase platform. The company's lead therapeutic candidate, efzofitimod, is currently in a Phase 3 EFZO-FIT study for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease. 1. **Analyst Ratings and Price Target**: - H.C. Wainwright has reiterated its Buy rating on aTyr Pharma with a price target of $35.00. - The average one-year price target from analysts is $24.60, with a high estimate of $35.00 and a low estimate of $16.00. - The consensus recommendation from brokerage firms is an "Outperform" status. 2. **Recent Developments**: - aTyr Pharma has completed the last patient's visit in its Phase 3 EFZO-FIT study, with topline results expected in the third quarter of 2025. - The company has reported positive interim results from its Phase 2 study of efzofitimod for treating systemic sclerosis-related interstitial lung disease (SSc-ILD), showing clinically significant improvements in patients. - aTyr Pharma is set to be included in the Russell 2000 and Russell 3000 indexes, marking its recognition among the largest publicly traded U.S. companies. 3. **Insider Activity**: - aTyr Pharma insiders have shown confidence in the company, with significant purchases of shares over the past year. For instance, Independent Director Paul Schimmel purchased shares worth $185k. - The company's market capitalization increased by $61 million, translating to a gain of 211% on the initial investment made by insiders. In conclusion, while no ATYR stocks were found, aTyr Pharma (NASDAQ: ATYR) is a promising biotechnology company with a strong research pipeline and positive analyst ratings. The completion of its Phase 3 EFZO-FIT study and the anticipated topline results could be a catalyst for stock price appreciation.